IKNA
Income statement / Annual
Last year (2023), Ikena Oncology, Inc.'s total revenue was $9.16 M,
a decrease of 41.35% from the previous year.
In 2023, Ikena Oncology, Inc.'s net income was -$68.17 M.
See Ikena Oncology, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$9.16 M
|
$15.62 M
|
$30.99 M
|
$9.19 M
|
$13.75 M
|
$990,000.00
|
| Cost of Revenue |
$59.65 M |
$2.03 M |
$47.11 M |
$44.85 M |
$24.94 M |
$38.99 M |
| Gross Profit |
-$50.49 M |
$13.58 M |
-$16.12 M |
-$35.65 M |
-$11.19 M |
-$38.00 M |
| Gross Profit Ratio |
-5.51 |
0.87 |
-0.52 |
-3.88 |
-0.81 |
-38.38 |
| Research and Development
Expenses |
$59.65 M
|
$64.32 M
|
$47.11 M
|
$44.85 M
|
$24.94 M
|
$38.56 M
|
| General & Administrative
Expenses |
$24.93 M
|
$22.20 M
|
$18.02 M
|
$8.87 M
|
$7.31 M
|
$2.90 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$24.93 M
|
$22.20 M
|
$18.02 M
|
$8.87 M
|
$7.31 M
|
$2.90 M
|
| Other Expenses |
$0.00 |
-$10,000.00 |
$23,000.00 |
$263,000.00 |
$1.68 M |
$0.00 |
| Operating Expenses |
$84.58 M |
$86.52 M |
$65.12 M |
$53.71 M |
$32.25 M |
$41.46 M |
| Cost And Expenses |
$84.58 M |
$86.52 M |
$65.12 M |
$53.71 M |
$32.25 M |
$41.88 M |
| Interest Income |
$7.11 M |
$2.15 M |
$23,000.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
$2.15 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.02 M
|
$2.03 M
|
$1.72 M
|
$1.26 M
|
$122,000.00
|
$422,000.00
|
| EBITDA |
-$74.40 M
|
-$70.15 M
|
-$33.59 M
|
-$44.22 M
|
-$18.25 M
|
-$40.44 M
|
| EBITDA Ratio |
-8.12 |
-4.49 |
-1.08 |
-4.81 |
-1.33 |
-40.88 |
| Operating Income Ratio
|
-8.23
|
-4.54
|
-1.1
|
-4.84
|
-1.34
|
-41.31
|
| Total Other
Income/Expenses Net |
$7.09 M
|
$2.14 M
|
$23,000.00
|
$263,000.00
|
$1.68 M
|
$29,000.00
|
| Income Before Tax |
-$68.33 M |
-$68.77 M |
-$34.12 M |
-$44.26 M |
-$16.82 M |
-$40.87 M |
| Income Before Tax Ratio
|
-7.46
|
-4.4
|
-1.1
|
-4.81
|
-1.22
|
-41.28
|
| Income Tax Expense |
-$162,000.00 |
-$2.14 M |
$307,442.00 |
$93,703.00 |
$71,140.00 |
$0.00 |
| Net Income |
-$68.17 M |
-$66.63 M |
-$34.12 M |
-$44.26 M |
-$16.82 M |
-$40.87 M |
| Net Income Ratio |
-7.44 |
-4.27 |
-1.1 |
-4.81 |
-1.22 |
-41.28 |
| EPS |
-1.63 |
-1.84 |
-0.95 |
-1.23 |
-0.47 |
-1.14 |
| EPS Diluted |
-1.63 |
-1.84 |
-0.95 |
-1.23 |
-0.47 |
-1.14 |
| Weighted Average Shares
Out |
$41.74 M
|
$36.19 M
|
$35.98 M
|
$35.85 M
|
$35.85 M
|
$35.85 M
|
| Weighted Average Shares
Out Diluted |
$41.74 M
|
$36.19 M
|
$35.98 M
|
$35.85 M
|
$35.85 M
|
$35.85 M
|
| Link |
|
|
|
|
|
|
